TARGETED THERAPY

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific type of colorectal cancer (MSS/pMMR) will…

This phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…

This large phase 3 study is testing different combinations of chemotherapy, radiation, immunotherapy, and targeted drugs given before surgery for esophageal cancer. The goal is to find which approach works best to improve survival. The trial will enroll 2,000 adults with stage I …

This study is looking at the best way to treat esophageal cancer that cannot be removed by surgery. It will follow 2,000 patients who receive chemoradiotherapy (radiation plus chemotherapy) along with possible immunotherapy or targeted drugs. The goal is to see which combinations…

This study is for people with locally advanced rectal cancer that hasn't spread. It tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation plus chemotherapy and targeted therapy) can lead to a complete disappearance of the…

This study is testing a new program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage their cancer. Re…

This study looks at whether a patient's emotional state—like depression or anxiety—affects how well advanced liver cancer treatment works. Researchers will follow 90 people with liver cancer who are getting a combination of chemotherapy, targeted therapy, and immunotherapy. They …

This early-phase trial tests a new drug called SOB100, which uses tiny particles called exosomes to target a protein named HLA-G. The study involves 15 healthy adults to check if the drug is safe and how the body processes it. No treatment benefit is expected; the goal is to gath…